This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "heme_biosynthesis_porphyria#Accumulation of Porphyrin Precursors and Porphyrins"). The single best key conformance target is the central "Accumulation of Porphyrin Precursors and Porphyrins" node — the one event every porphyria shares regardless of arm. Conforming nodes should substitute the disorder-specific lesion: the deficient (or, for ALAS2, hyperactive) enzyme at the trigger node, the accumulating intermediate at the central node (ALA/PBG for the acute hepatic arm; uroporphyrin/coproporphyrin/protoporphyrin IX for the cutaneous-erythropoietic arm), and the relevant effector arm (neurovisceral vs. cutaneous). An acute-hepatic conformer routes through the neurovisceral-neurotoxicity effector; a cutaneous or erythropoietic conformer routes through the phototoxicity effector; overlap porphyrias (hereditary coproporphyria, variegate porphyria) may route through both. Chemistry (ALA, PBG, porphyrins) and the enzyme/gene identities are given in prose; modules bind GO and CL terms only and do not use CHEBI or gene bindings. Disease-specific chronic sequelae (AIP hepatocellular carcinoma and chronic kidney disease, EPP hepatobiliary liver injury, CEP transfusion-dependent hemolytic anemia) belong on the individual disorder entries, not this module. Acquired chemical inhibition of a single heme-pathway enzyme — lead's inhibition of ALAD and ferrochelatase, or succinylacetone's inhibition of ALAD in hereditary tyrosinemia type I — produces the same block -> accumulation chain as the genetic porphyrias and conforms to the same node set; conforms_to here is a claim about the shared enzymatic-block mechanism, not about heritability. See Lead_Poisoning for a worked acquired conformer.
Heme Biosynthesis Enzymatic Block
trigger
The conserved initiating lesion is a pathogenic partial deficiency of one of the enzymes of the heme biosynthetic pathway (or, in X-linked protoporphyria, a gain of function of erythroid ALAS2). The block interrupts normal porphyrin metabolism and primes the affected compartment — hepatic or erythroid — for accumulation of the intermediates immediately upstream of the defective step.
Downstream
-
Accumulation of Porphyrin Precursors and Porphyrins
Show evidence (1 reference)
"The porphyrias are a group of rare diseases, each resulting from a defect in a different enzymatic step of the heme biosynthetic pathway."
Establishes the conserved trigger — a subtype-specific enzymatic defect in heme biosynthesis. Evidence source is OTHER because this is a review synthesizing the disease class.
Accumulation of Porphyrin Precursors and Porphyrins
central effector
Behind the enzymatic block, the pathway intermediates immediately upstream of the lesion accumulate to pathological concentrations. The identity of the accumulating species is subtype-specific — the porphyrin precursors 5-aminolevulinic acid (ALA) and porphobilinogen (PBG) in the acute hepatic porphyrias, and the porphyrins uroporphyrin, coproporphyrin, or protoporphyrin IX in the cutaneous and erythropoietic porphyrias — but the accumulation of heme intermediates upstream of the block is the shared central lesion. In the acute hepatic porphyrias the accumulation is conditional: a compensated carrier state is converted to overproduction only when hepatic ALAS1, the first and rate-limiting enzyme of the pathway, is induced by porphyrogenic triggers (drugs, fasting, alcohol, hormonal cycling, or intercurrent illness).
Downstream
-
Neurovisceral Precursor Neurotoxicity
-
Cutaneous Porphyrin Phototoxicity
Show evidence (2 references)
"They can be broadly divided into two categories, hepatic and erythropoietic porphyrias, depending on the primary site of accumulation of heme intermediates."
Supports the shared central lesion — accumulation of heme intermediates — with branch specificity by tissue compartment. Evidence source is OTHER because this is a review article.
"Pathogenic variants in 1 of 4 enzymes of heme synthesis are necessary for the development of AHP, and the onset of acute attacks also requires the induction of δ-aminolevulinic acid synthase 1 (ALAS1), the first and rate-limiting step of heme synthesis in the liver."
Supports the conditional-accumulation mechanism of the acute hepatic arm — an inherited enzyme defect plus hepatic ALAS1 induction drives precursor overproduction. Evidence source is OTHER because this is a review article.
Neurovisceral Precursor Neurotoxicity
effector
In the acute hepatic porphyrias, overproduced ALA and PBG are the proximate drivers of the acute neurovisceral attack. The accumulated precursors — ALA in particular is a recognized pro-oxidant neurotoxin — injure the autonomic, peripheral, and central nervous systems, producing the characteristic attack of severe abdominal pain, autonomic instability, motor-predominant axonal neuropathy, and neuropsychiatric disturbance. Silencing hepatic ALAS1 to lower ALA and PBG prevents attacks, establishing precursor burden as the causal driver.
Show evidence (2 references)
"The acute hepatic porphyrias (AHPs) are a family of rare genetic diseases associated with attacks of abdominal pain, vomiting, weakness, neuropathy, and other neurovisceral symptoms."
Links the acute hepatic porphyria arm to the neurovisceral attack phenotype. Evidence source is OTHER because this is a review article.
"Givosiran (siRNA) is an emerging AIP therapy capable of silencing delta-aminolevulinic acid synthase-1 (ALAS1) and, in turn, reducing the accumulation of delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) that precede porphyria symptoms."
Supports precursor accumulation as the causal antecedent of neurovisceral symptoms — lowering ALA and PBG via ALAS1 silencing prevents them.
Cutaneous Porphyrin Phototoxicity
effector
In the cutaneous and erythropoietic porphyrias, the accumulating species are photoreactive porphyrins (uroporphyrin and coproporphyrin in congenital erythropoietic porphyria and porphyria cutanea tarda; protoporphyrin IX in erythropoietic protoporphyria and X-linked protoporphyria). On absorbing visible light these porphyrins enter an excited state and transfer energy to molecular oxygen, generating reactive oxygen species (notably singlet oxygen) that damage skin and erythrocytes. The clinical result ranges from the acute, non-blistering phototoxic pain of the protoporphyrias to the fragile, blistering, scarring bullous photodermatitis of the uroporphyrin-accumulating porphyrias.
Show evidence (2 references)
"Both of these abnormalities result in the buildup of protoporphyrin IX, leading to excruciating light sensitivity and, in a minority of cases, potentially fatal liver complications."
Links protoporphyrin IX accumulation to light-triggered phototoxicity in the protoporphyria branch. Evidence source is OTHER because this is a review article.
"This in turn leads to the accumulation of the non-physiologic and photoreactive porphyrinogens, uroporphyrinogen I and coproporphyrinogen I, which damage erythrocytes and elicit a phototoxic reaction upon light exposure."
Supports the phototoxicity arm — photoreactive porphyrin(ogen) accumulation damages erythrocytes and elicits a light-triggered phototoxic reaction in the erythropoietic branch.